CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

Home About What We Do Programs and Services CADTH Reimbursement Review Infliximab

Infliximab

Last Updated: May 30, 2014

Result type: Reports

Project Number: SE0383-000

Product Line: Reimbursement Review

Generic Name: Infliximab

Brand Name: Remsima

Manufacturer: Fresenius Kabi Canada

Therapeutic Area: Ankylosing spondylitis; arthritis, psoriatic; arthritis, rheumatoid; plaque psoriasis

Indications: Ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis

Submission Type: Initial

Project Status: Withdrawn

Biosimilar: Yes

Infliximab

Files